This novel anti-infective, invented by Orchid Pharma, aims to address the rising threat of antimicrobial resistance (AMR) and has been approved for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP)
Read More
The transaction has been executed through the Kotak Strategic Situations Fund II
Read More
"The Indian pharmaceutical market for chronic diseases is experiencing significant growth. By leveraging our expertise in chronic therapies and dedication to innovation and brand development, JB Pharma is well-positioned to continue its upward trajectory in the Indian pharmaceutical market." - Dilip Singh Rathore, President-India Business, JB Pharma
Read More
Technology, skills and learnings are industry-agnostic. It's your mindset that enables the implementation of a basic idea from one industry into something revolutionary in another says Priyanka
Read More
Established in 2011 as a 50:50 joint venture for pharmaceutical sales and marketing in India, Bayer has now acquired the remaining 25 per cent stake to secure full ownership of the entity, in accordance with pre-agreed joint venture terms
Read More
The ‘Cure and Beyond’ campaign not only aims to spotlight innovation as the cornerstone of Emcure's operations but also endeavors to instill a sense of thought leadership within the Indian pharmaceutical sector
Read More
